Leading research foundation for the diagnosis and treatment of Pancreatic Cancer

Developing transformative medicines that dramatically improve the lives of patients with immune & inflammatory diseases. Lead program, TOUR001, is an anti-IL6L for treatment of autoantibody mediated diseases and inflammatory cardiovascular disorders.NASDAQ: TRML

Targeted Radiotherapy. Acquired by Bristol Myers Squibb for $4.1B.

NASDAQ: CNTA

Leading metabolic disease company. Developing a long-acting Fc Fusion modified fibroblast growth factor 21 (FGF21), AKR-001, for NASH and other metabolic diseases. NASDAQ: AKRO

Developing precision medicines for cardiovascular disease Acquired by Novo Nordisk for $2.1B in total cash considerations

Elstar Therapeutics is leveraging recent technological advances in antibody engineering to generate best-in-class multi-specific and multi-functional immunotherapies. These molecules harness our growing understanding of immune modulation to treat a variety of hematological malignancies and solid tumors.

Apple Tree Partners (ATP), is a venture capital firm that invests in and builds biotech companies.

Limelight Bio (now Ascidian & Intergalactic) is using proprietary technologies to develop novel gene therapies that overcome key limitations of traditional gene replacement: payload capacity (restricting gene size) and re-dosing (restricting efficacy and durability).

Syntimmune is developing novel antibody therapies for inflammatory and autoimmune diseases. Syntimmune’s lead program, SYNT-001, specifically blocks FcRn-IgG interaction, resulting in the rapid clearance of pathogenic IgG important in a variety of antibody-mediated diseases. Acquired by Alexion for $1.2B in total cash considerations.

Braeburn Pharmaceuticals, an Apple Tree Partners company, is dedicated to developing and commercializing new long-acting treatment options for individuals with serious neurological and psychiatric disorders, including pain and addiction